The Venture Codex

Participated · Equity · Feb 2025

Founded in 2022 by CEO Rachel Edenfield, Swell develops scalable, AI-driven mental health tools that supplement traditional therapy and broaden access in underserved markets such as military communities. The company built an MVP and began generating revenue within five months of inception, then launched a full beta at Fort Campbell two months later. Swell has since secured contracts with Tricare and Humana Military, expanded its provider network across Kentucky and Tennessee, and filed a patent for a HIPAA-compliant AI intermediary that powers its self-guided therapy prototype. The startup was also accepted into the Awesome Fellowship, underscoring early validation of its approach. Looking ahead, management plans to grow both its client and therapist bases to accelerate revenue and aims to win a development contract with the Department of Veterans Affairs for its AI-enabled product. The recent capital raise will fund continued product development and operational expansion.

Participated · Series A · Oct 2018

Lumenari develops narrow-bandwidth LED phosphors, offering its flagship Emerald phosphor to expand color gamut and range in displays including televisions, tablets, laptops, monitors and smartphones. Emerald is positioned to minimize brightness degradation and color shift while enabling wider color gamut displays. The company says the funds will accelerate its go-to-market strategy with OEMs, packaged LED suppliers and display manufacturers. Lumenari was launched in 2013 and relocated from Silicon Valley to Lexington, Kentucky. The display panel market was valued at $164 billion in 2017 and is projected to reach $235 billion by 2023, supporting demand for wider color-gamut solutions. The company emphasizes commercial deployment in LCD display backlighting applications.

Participated · Series A · Feb 2014

TNG Pharmaceuticals is a Louisville, KY–based animal pharmaceutical company developing FlyVax™, a patented vaccine intended to reduce damage from horn flies in cattle. FlyVax was first developed by research scientists at Auburn University and licensed by TNG, and has shown effectiveness in initial laboratory testing. The company completed a $4.6 million Series A Preferred Stock financing to fund completion of all phases of product development and move toward commercialization. TNG says the financing will allow it to commercialize the vaccine in a timely fashion. The company originated at the University of Louisville in the Entrepreneurship MBA program and was named the 2011 Global Business Plan Champion. Management positions the product as offering significant health and economic benefits for the cattle industry.

Participated · Series C · Apr 2010

Allylix uses a fermentation-based, metabolic and protein engineering technology platform to produce terpenes and their derivatives for flavor & fragrance, food ingredients, cosmetics and other markets. The platform enables creation of highly pure, renewable compounds that were previously available only from limited natural resources. Allylix’s technology is protected by 57 patents and is positioned to rapidly develop and produce high-value specialty chemicals at lower cost than traditional methods. The company says it can deliver high-quality products at scalable commercial quantities and at a lower price point. Proceeds from the recent financing are intended to support development and delivery of new compounds in Allylix’s pipeline and to expand the market for its existing products. Allylix develops terpene products and their derivatives for multiple end markets including flavor and fragrance, food ingredients, pharmaceuticals, agriculture and biofuels. The company is based in San Diego, CA. Its near-term commercial focus is on three initial products for the flavor and fragrance industry. The financing described in the article is intended to commercialize those initial products and to advance other products in its pipeline. No operating metrics (revenue or users) are disclosed in the article. Allylix develops a metabolic engineering platform to enable low-cost production of terpene products through yeast fermentation. The platform is protected by 28 patents with additional applications pending and is applicable across flavors and fragrances, food ingredients, fine chemicals, pesticides/crop protection and pharmaceuticals. The company’s first product is nootkatone, a long‑lasting citrus flavor and fragrance used in food, beverage and personal care industries. Allylix plans to commercialize its first three products for the food and fragrance industry and to advance several additional pipeline products. The company previously licensed its technology for specific biofuels products in 2008. The business is based in San Diego, CA. Allylix develops chemicals for the flavor, fragrance, pharmaceutical, nutraceutical, and agricultural markets. Its products are based on terpenes and the company planned six initial products. The company said new funding will be used to launch the first three of those six products. Allylix raised $3.35M in a venture round. Investors in the round included Tech Coast Angels, Life Science Angels, Blue Grass Angels, Pasadena Angels, and Tate & Lyle Ventures; the Tech Coast Angels' lead investor on the deal was Stephen Block. Allylix maintains business operations in San Diego and research and development in Lexington, Kentucky.